VIVEbiotech
San Sebastián, Spain
Program data pending ClinicalTrials.gov matching
55.0
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (10)
○ EMA GMP
○ MHRA GMP
Quick Facts: VIVEbiotech
- Signal Score
- 55.0/100
- Quality Compliance
- Assessment pending
- Headquarters
- San Sebastián, Spain
- Modalities
- Lentiviral
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About VIVEbiotech
Auto-created by AI matchmaker. Data verification pending.
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesLentiviral
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
50.0
Manufacturing site information being gathered
Modalities: Lentiviral
Capacity assessment: 50.0/100
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Recent Press10 articles
Manufacturing site information being gathered
Modalities: Lentiviral
Capacity assessment: 50.0/100
Recent News 10 articles
VIVEbiotech Secures Growth Investment from Ampersand Capital Partners to Expand Lentiviral Vector Development and Manufacturing Capabilities - PR Newswire
VIVEbiotech Secures Investment to Expand Lentiviral Vector Manufacturing - Contract Pharma
CDMOs Invest in Biomanufacturing, Cell- & Gene-Therapy Manufacturing - DCAT Value Chain Insights
VIVEbiotech Lentiviral Vector Manufacturing Plant, San Sebastian, Spain - Pharmaceutical Technology
CDMO Vibalogics, speeding toward U.S. commercial plant, pumps $50M into viral vector capacity - Fierce Pharma
Vexed by vectors: How COVID-19 vaccine and cell and gene players are tackling the viral vector bottleneck - Fierce Pharma
How to Find Success with Lentiviral Production Using Fixed Bed Bioreactor Technology - BioPharm International
Advances in manufacturing in vivo lentiviral vectors: Challenges and solutions - pharmaphorum
With demand surging for lentiviral vectors, CDMO VIVEbiotech expands capacity 400% in cross-town move - Fierce Pharma
England's drug price watchdog rejects Orchard's groundbreaking gene therapy after first round of talks - Fierce Pharma
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Pharmaron Biologics
San Diego, CA · Shaoxing, CN
Signal Score: 85.6
AAV, Lentiviral, Plasmid
August Bioservices
San Carlos, CA
Signal Score: 77.4
AAV, Lentiviral
3P Biopharmaceuticals (now 3PBIOVIAN)
Pamplona-Noáin, Spain
Biologics (microbial & mammalian), AAV, Adenoviral, Lentiviral, Cell Therapy, Plasmid DNA, Recombinant Proteins, Biosimilars, Fill/Finish (recombinant proteins & viral vectors)
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 91.7
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral
ReciBioPharm
Keele, UK · Sodertalje, SE
Signal Score: 88.0
AAV, Lentiviral, Plasmid, mRNA